| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4901 | SS-lysine | Elongation factor P (EF-P) fuction modifier |
|
| DCC4902 | Ssm3 Tfa Salt | Potent furin inhibitor, blocking furin-dependent cell surface processing of anthrax protective antigen-83 in vitro. |
|
| DCC4903 | SS-nf-atra | Novel chimeric degrader against cellular retinoic acid binding proteins (CRABPs), inducing the AhR-dependent degradation of CRABP-1 and CRABP-2 via the ubiquitin-proteasome pathway |
|
| DCC4904 | SS-nf-jq1 | Novel chimeric degrader against bromodomain-containing (BRD) proteins, inducing the interaction of AhR and BRD proteins and displaying effective anticancer activity that correlated with protein knockdown activity |
|
| DCC4905 | SS-nicotinamide Adenine Dinucleotide, Reduced Disodium | Cofactor for mitochondrial deacetylase sirtuin-3 enzyme, regulating energy metabolism and immunity and modulating inflammasome assembly |
|
| DCC4906 | Ssr126768a | Novel Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor |
|
| DCC4907 | Ssr180575 Featured | SSR-180,575 is a drug which acts as a selective agonist at the peripheral benzodiazepine receptor, also known as the mitochondrial 18 kDa translocator protein or TSPO. It has been shown to have neuroprotective and cardioprotective effects and to stimulate steroidogenesis of pregnenolone in the brain, which may be linked to its neuroprotective action. |
|
| DCC4908 | SS-thujaplicinol | Inhibitor of the replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) |
|
| DCC4909 | Sstr3-agonist-5c | Novel non-peptidic highly potent somatostatin receptor 3 (SSTR3) agonist |
|
| DCC4910 | Sstr3-antagonist-3a | Novel potent sstr3 antagonist, showing to reduce glucose excursion in a mouse oGTT assay |
|
| DCC4911 | Sstr5a | Novel somatostatin receptor subtype 5 antagonist, stimulating glucoseinduced GLP-1 secretion, reducing blood glucose in a gut- and GLP-1R-dependent manner |
|
| DCC4912 | St026567 | Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
| DCC4913 | St029248 | Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
| DCC4914 | St056083 | Novel inhibitor of the c-di-AMP synthetase DNA integrity scanning protein (DisA) in vitro |
|
| DCC4915 | St101036 | Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
| DCC4916 | st-1032 | Novel histamine H3 receptor ligand |
|
| DCC4917 | St1237 | Potent, direct, non-cytotoxic Arachidonate_5-lipoxygenase>5-lipoxygenase (5-LO) inhibitor |
|
| DCC4918 | St-161 | Antiviral agent against LASV and a number of other viruses in the Arenaviridae family |
|
| DCC4919 | St-1703 | Novel histamine H3 receptor ligand |
|
| DCC4920 | St-1892 | Novel highly potent and soluble partial FXR agonist |
|
| DCC4921 | St-198 | Seletive dopamine D3 receptors |
|
| DCC4922 | St-1992 | Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
| DCC4923 | St-2001 | Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
| DCC4924 | St-2262 | Novel selective NaV1.7 inhibitor, blocking the extracellular vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1-1.6 and NaV1.8 |
|
| DCC4925 | St4070 | Highly selective FAAH>fatty acid amide hydrolase (FAAH) inhibitor |
|
| DCC4926 | St7710aa1 | Novel PARP-1 inhibitor, showing significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp |
|
| DCC4927 | Sta-9584 | Novel tubulin-binding vascular disrupting agent (VDA) |
|
| DCC4928 | Stad-2 | Cell permeable AKAP disruptor, selectively binding to PKA-RII and blocking the interaction of PKA-RI with AKAP |
|
| DCC4929 | Stalobacin I | Novel Lipopeptide Antibiotic with Potent Antibacterial Activity against Multidrug-Resistant Bacteria |
|
| DCC4930 | Stanozolol [10418-03-8] | Anabolic-androgenic steroid (AAS), acting as an agonist of the androgen receptor (AR) |
|
